India has a stock of 7.5 lakh doses of Oseltamivir drugs to combat avian flu — enough to treat 75,000 people. After today’s reports confirming the disease in chicken samples, an additional order has been placed for 2.5 lakh doses.
While Hetero Drugs has been licenced by the government of India for manufacturing, other companies claim they are ready and waiting to face the needs.
While Roche is the original Swiss patent holder, Cipla and Ranbaxy have made copies of the original and have got orders from countries where the patent regime is no so water-tight.
With the list of countries where cases are being reported is growing every week, orders are flowing in for all these companies. A company like Ranbaxy that is not ready for the next 3-4 months has got orders from 15 countries in its bag.
To administer it as a precautionary drug—it may result in the virus developing resistance.
With the first cases of bird flu in poultry, the government is not taking chances now: Hetero Drugs said it has got an order from the Government for an additional two lakh capsules. ‘‘We will deliver another two lakh capsules in the next three-four days,’’ director Hetero Drugs, Srinivas Reddy said in Hyderabad.
Reddy said the company has active pharmaceutical ingredient API of the drug equivalent of one million capsules in stock. ‘‘It would need seven days for the API to be made into capsules,’’ he said. The company had supplied the medicine to the government at a rate of Rs 710 per strip of 10 capsules.
Ranbaxy says it can only supply it ‘‘in the second half of the year’’. The toxicity and bioequivalence tests are on before which they cannot start bulk manufacture.
Chairman of Cipla Dr Yusuf Hamied today said he had been warning the government about the dangers of bird flu but the government response has been lukewarm. ‘‘It’s a shame… we kept warning about this but no one listened to us,” he said. ‘‘We are ready to supply the drugs by next week… but no one from the government show any interest in the drug,’’ the 67-year old Dr Hamied said.
There was a discussion then whether India should, in “national interest”, break the patent regime and not sign on World Trade Organisation agreements which makes it mandatory for any government to first declare a ‘‘national emergency’’ on medical ground, get it ratified with WTO and then allow Indian companies to make the medicine.
However, being signatory to TRIPPS, it has to follow the patent rules. When the world was waking up to the risk of bird flu last October, Cipla had decided to break Roche’s patent on its own and make the drug for India and for exporting it to those 49 countries where Roche has not been given the patent.Company representatives, however, say that the drug can only be administered when humans display symptoms — cough, cold and runny nose. It is to be administered within 48 hours for five days. However, it is not advisable